4.3 Article

CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer

期刊

VIRCHOWS ARCHIV
卷 480, 期 4, 页码 819-829

出版社

SPRINGER
DOI: 10.1007/s00428-021-03230-2

关键词

CD109; Immunohistochemistry; Pancreatic cancer; Prognostic marker; Progression

资金

  1. JSPS KAKENHI [JP18H02643]
  2. 2018 Parents' Association Grant of Kitasato University School of Medicine
  3. Kitasato University Graduate School of Medical Sciences
  4. Health Science Center Foundation

向作者/读者索取更多资源

CD109 expression in both tumor cells and stroma is significantly associated with the progression and prognosis of pancreatic ductal adenocarcinoma (PDAC), and may serve as a valuable prognostic marker.
CD109 is a glycosylphosphatidylinositol-anchored glycoprotein, whose expression is upregulated in some types of malignant tumors. High levels of CD109 in tumor cells have been reported to correlate with poor prognosis; however, significance of CD109 stromal expression in human malignancy has not been elucidated. In this study, we investigated the tumorigenic properties of CD109 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis of 92 PDAC surgical specimens revealed that positive CD109 expression in tumor cells was significantly associated with poor prognosis (disease-free survival, p = 0.003; overall survival, p = 0.002), and was an independent prognostic factor (disease-free survival, p = 0.0173; overall survival, p = 0.0104) in PDAC. Furthermore, CD109 expression was detected in the stroma surrounding tumor cells, similar to that of alpha-smooth muscle actin, a histological marker of cancer-associated fibroblasts. The stromal CD109 expression significantly correlated with tumor progression in PDAC (TNM stage, p = 0.033; N factor, p = 0.024; lymphatic invasion, p = 0.028). In addition, combined assessment of CD109 in tumor cells and stroma could identify the better prognosis group of patients from the entire patient population. In MIA PaCa-2 PDAC cell line, we demonstrated the involvement of CD109 in tumor cell motility, but not in PANC-1. Taken together, CD109 not only in the tumor cells but also in the stroma is involved in the progression and prognosis of PDAC, and may serve as a useful prognostic marker in PDAC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据